(PharmaNewsWire.Com, October 16, 2019 ) The global insulin resistance market is forecasted to grow at a stable CAGR of around 4.2% during the forecast period of 2019 to 2026.
A rise in the prevalence of diabetes and obesity globally, rise in sedentary lifestyle of general population, and increase in favorable government initiatives are some of the fundamental factors that are driving the insulin resistance market growth across the globe
Insulin resistance is defined as impaired insulin-stimulated glucose uptake. In a broader sense, insulin resistance can be referred to as desensitization of the body's response to insulin encompassing growth, development, and metabolism. Insulin resistance impairs glucose disposal, resulting in a compensatory increase in beta-cell insulin production and hyperinsulinemia. Asia-Pacific is anticipated to witness the highest growth rate over the forecast period owing to high body mass index (BMI), sedentary lifestyle, a high percentage of smoking population, bad eating habits, rise in diabetes and air population.
Growing health burden and risks associated with increasing incidence rates and prevalence population of chronic diseases, especially - obesity and diabetes, is a key driver boosting the market value for drugs being prescribed for insulin resistance. Change in lifestyle, higher consumption of fast food, increase in age, and certain other medical conditions such as PCOS, osteoarthritis, and many others are the reason for rise in obesity globally. Obesity is not just a common cosmetic concern. Obesity is a complex disorder and can lead to insulin resistance due to excess body fat. In addition to insulin resistance, it represents a severe risk factor for several chronic diseases, such as cardiovascular diseases (including hypertension), diabetes, prediabetes. Globally, several national and international organizations have implemented several initiatives that can enhance the disease awareness of diabetes and can help to improve preventive measures to diminish the disease incidence rates. The initiatives launched to prevent diabetes, in turn, increase the awareness levels of the underlying conditions which include – insulin resistance and pre-diabetes, thereby boosting the overall market growth.
Biguanides to Grow at Highest Rate in Insulin Resistance Market
By drug class, the global insulin resistance market is segmented into Biguanides, Thiazolidinediones, Glucagon-like Peptide 1 (GLP-1) Receptor Agonists, Concentrated Insulin Products, Sodium-glucose Cotransporter 2 (SGLT2) Inhibitors, Dipeptidyl Peptidase-4 (DPP-4) Inhibitors, and Others. Biguanides are expected to hold the largest market share of 43.5% over the period of forecast as Biguanides lowers insulin resistance, by making muscles of our body use insulin better so glucose can get into them instead of staying in the blood. Biguanides prevent the liver from converting fats and amino-acids into glucose. They activate an enzyme (AMPK) that helps cells to effectively respond to insulin and take in glucose from the blood. Metformin is the most common biguanide and the most prescribed drug for insulin resistance. Metformin demonstrates a positive impact on glycemic control and weight management. Insulin resistance is more common in obese people; hence the drug helps curb the appetite thus reducing weight and decreasing insulin resistance.
By disease co-morbidity, the global insulin resistance market is divided into Diabetes, Pre-Diabetes, Metabolic Syndrome, Hypertension, Obesity, Healthy Obese, Dyslipidemia, PCOS, Alzheimer’s Disease, Depression, Acromegaly, Glaucoma and Gastrointestinal Disorders (NAFLD, NASH). Diabetes is expected to grow at the highest CAGR over the period of the forecast as Insulin resistance precedes the development of type 2 diabetes. A person suffering from insulin resistance is at a higher risk of developing diabetes. Approximately more than 90% of the total diabetes patients (type 2 diabetic patient pool) are said to have insulin resistance that indicates proper production of insulin, but lack of its functionality and usage.
Asia-Pacific to Grow at Highest Rate in Insulin Resistance Market
Geographically, the global insulin resistance market has been divided into North America, South America, Europe, Asia Pacific, and the Middle East and Africa. Asia-Pacific is forecasted to witness high growth and grow at highest CAGR during the forecast period owing to the rising of BMI level among general population, with less muscle and more abdominal fat. Increase in smoking habits among population, high consumption of junk food, and low awareness on proper nutrition and food hence majority of population consume white rice and other refined grains, which are linked to increased risk of diabetes. North America is expected to hold the dominant market share over the forecast period due to rise in cases of diabetes and other co-morbid diseases and lifestyle changes among general population. Increasing cases of diabetes and other co-morbid disorders are the key factor fuelling the regional market growth as insulin resistance is the key symptom of type 2 diabetes. The percentage of population suffering from type 2 diabetes are definitely suffering from insulin resistance.
The global insulin resistance market is highly fragmented, with none of the players occupying a significant market share. The company profiling of key players in the market includes major business strategies, company overview, and revenues. The key players of the market are AstraZeneca, Bristol-Myers Squibb, Eli Lilly and Company, Merck & Co., Nova Nordisk, Teva Pharmaceuticals, Sanofi, GlaxoSmithKline, Mylan, and Takeda Pharmaceuticals.
DataM Intelligence was incorporated in the early weeks of 2017 as a Market Research and Consulting firm with just two people on board. Within a span of less than a year we have secured more than 100 unique customers from established organizations all over the world.
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including:
